eGenesis
1 Kendall Square
Building 200, 2nd Floor, Suite 2203
Cambridge
Massachusetts
02139
United States
Website: http://www.egenesisbio.com/
About eGenesis
eGenesis is a life sciences company focused on leveraging CRISPR technology to deliver safe and effective human transplantable cells, tissues and organs to the hundreds of thousands of patients worldwide who are in dire need.YEAR FOUNDED:
2015
LEADERSHIP:
C?o-Fou?nder and Advisor: George M. Church, Ph.D
Co-Founder and CSO: Luhan Yang, Ph.D
Managing Director: Geoff Mackay
Founding Scientist: Marc Guell, Ph.D.
CAREER:
Please click here for eGenesis' job opportunities.
37 articles about eGenesis
-
eGenesis and PorMedTec Announce Successful Production of Genetically Engineered Porcine Donors in Japan
2/13/2024
eGenesis and PorMedTec have successfully produced genetically engineered porcine donors in Japan for use in transplantation.
-
eGenesis and OrganOx Announce Successful Use of a Genetically Engineered Porcine Liver with a Human Donor
1/18/2024
eGenesis and OrganOx today announced the successful completion of an extracorporeal perfusion of a brain-dead research donor using a genetically engineered porcine liver.
-
eGenesis Presents Preclinical Data Demonstrating Recipient Survival and Compatibility with Genetically Engineered Porcine Kidneys at 2023 IPITA-IXA-CTRMS Joint Conference
10/26/2023
eGenesis will present new data and host a symposium during the IPITA (International Pancreas and Islet Transplant Association), IXA (International Xenotransplantation Association), and CTRMS (Cell Transplant and Regenerative Medicine Society) joint congress, held in San Diego, October 26-29, 2023.
-
eGenesis Announces Publication in Nature of Landmark Preclinical Data Demonstrating Long-Term Survival with Genetically Engineered Porcine Kidneys
10/11/2023
eGenesis, a biotechnology company developing human-compatible (HuCo™) organs for the treatment of organ failure, today announced publication in the journal Nature of long-term survival data from a proof-of-concept study evaluating engineered porcine donor kidneys transplanted into a cynomolgus macaque model.
-
eGenesis Announces Publication in Nature Communications Characterizing Renal Physiology and Endocrine Function in Non-Human Primates Post Xenograft Transplant
6/13/2023
eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, announced the publication of a paper in the journal Nature Communications highlighting novel findings from the largest cohort of long-term non-human primate recipients of porcine kidney xenotransplantation to date.
-
eGenesis Presents New Data on Long-Term Survival in Preclinical Kidney Xenotransplantation at American Transplant Congress 2023
6/5/2023
eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, will present new data during the American Transplant Congress 2023, held June 3 – June 7, 2023 in San Diego, CA.
-
Karius and eGenesis partner to help accelerate xenotransplantation for patients in need of organ transplants
4/11/2023
Karius® and eGenesis, Inc. a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced a partnership through which the two companies will develop infectious disease diagnostics for xenotransplantation initially from porcine to primates and ultimately to humans.
-
eGenesis Announces Knut Niss as Chief Technology Officer
1/24/2023
eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss, Ph.D., has joined the company as Chief Technology Officer.
-
eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
1/9/2023
eGenesis, Inc. (“eGenesis”) and Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that they have entered into a collaborative research agreement under which eGenesis will gain access to Eledon’s anti-CD40L antibody candidate, tegoprubart, for eGenesis’ ongoing preclinical research and development studies of human-compatible organs and cells for the treatment of organ failure.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
eGenesis Promotes Michael Curtis, Ph.D., to Chief Executive Officer
4/19/2022
eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced the promotion of Michael Curtis, Ph.D., to Chief Executive Officer (CEO).
-
BioSpace Movers & Shakers, April 8
4/8/2022
Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week. -
eGenesis Appoints Eliezer Katz, M.D., FACS, as Chief Medical Officer
4/4/2022
eGenesis today announced the appointment of Eliezer Katz, M.D., FACS, as Chief Medical Officer (CMO).
-
eGenesis Announces Research Collaboration with the University of Miami to Evaluate Human Compatible Islet Cells in Diabetes Model
3/9/2022
eGenesis, a gene-editing company developing human-compatible (HuCo™) organs and cells, today announced the initiation of a research collaboration with the University of Miami Leonard M. Miller School of Medicine.
-
eGenesis Appoints Bradford Smith as an Independent Member of Its Board of Directors
6/9/2021
eGenesis announced the appointment of accomplished financial executive, Bradford Smith, Chief Financial Officer of Homology Medicines, Inc., as an independent member of the Board of Directors.
-
eGenesis Expands Research Collaboration with Leading Academic Medical Center
4/1/2021
eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the expansion of a research collaboration with Duke University School of Medicine.
-
BioSpace Movers & Shakers, March 5
3/5/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
eGenesis Appoints Veteran Financial Executive, Sapna Srivastava, Ph.D., as Chief Financial Officer
3/4/2021
eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the appointment of Sapna Srivastava, Ph.D., as Chief Financial Officer.
-
Xenotransplantation company eGenesis raised $125 million in a Series C financing round to drive the company’s lead programs in kidney and islet cell transplant into the clinic.
-
eGenesis Announces $125 Million Series C FinancingProceeds will advance two lead xenotransplantation programs in kidney failure and type 1 diabetes into first-in-human studies
3/2/2021
eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the successful completion of a $125 million Series C financing